European Journal of Clinical Pharmacy

Print ISSN: 2385-409X **Online ISSN**: Applied
Website: https://farmclin.es/

Original Research Article

Gemtuzumab Ozogamicin for the Treatment of Untreated Acute Myeloid Leukemia

Article History:

Name of Author:
Calzado Gomez G., Gavira Moreno R., Alegre Del Rey E.J. and Fenlx Caballero S.

Corresponding Author:
Calzado Gomez G.

How to cite this article:
Calzado Gomez G.., *et, al.* Gemtuzumab Ozogamicin for the Treatment of Untreated Acute Myeloid Leukemia. *Eur J Clin Pharm.* 2020;2(1);33.35.

Received: 20-06-2020
Revised: 28-06-2020
Accepted: 02-07-2020
Published: 25-07-2020

Abstract: Gemtuzumab ozogamicin (GO) is a CD33-targeted antibody-drug conjugate that has changed the frontline therapeutic landscape of acute myeloid leukemia (AML). After initial approval and withdrawal, modern fractionated dosing—especially in combination with standard chemotherapy—has demonstrated improvements in survival outcomes for newly diagnosed AML, primarily in patients with favorable or intermediate risk. This article reviews GO's mechanism of action, pivotal trial data, efficacy, safety, dosing, and current place in clinical practice.

Keywords: Gemtuzumab Ozogamicin (GO), Acute Myeloid Leukemia (AML), CD33-Targeted Therapy, Fractionated Dosing, Survival Outcomes.

INTRODUCTION

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with historically limited first-line options. The discovery of CD33 as a biomarker in most AML blasts paved the way for targeted therapies like gemtuzumab ozogamicin, an antibody-drug conjugate linking anti-CD33 immunoglobulin to the potent cytotoxin calicheamicin[1][2][3].

GO's journey has included initial FDA approval (2000), withdrawal due to safety concerns, and reapproval (2017) after pivotal studies established a new dosing paradigm with improved benefit-risk ratio, especially when paired with chemotherapy or in select monotherapy populations[4][3][5][6].

MECHANISM OF ACTION

- GO consists of a humanized anti-CD33 antibody conjugated to calicheamicin.
- After binding to CD33 on leukemic blasts, it is internalized, releasing calicheamicin and inducing double-strand DNA breaks and cell death[1][2].

Key Clinical Trials and Efficacy Data
ALFA-0701 Trial (Phase III)
A pivotal multicenter, randomized, open-label phase III trial (ALFA-0701) compared standard induction

chemotherapy (daunorubicin/cytarabine) with or without fractionated low-dose GO (3mg/m^2 on days 1, 4, 7) in adults aged 50–70 with previously untreated de novo AML:

- The addition of GO improved event-free survival (EFS): HR 0.66 (CI: 0.49–0.89; p=0.006)
- At two years: event-free survival 40.8% (GO arm) vs. 17.1% (control); overall survival 53.2% (GO arm) vs. 41.9% (control)
- The benefit was particularly marked in favorable/intermediate cytogenetic-risk patients[7][8][9][6]

[image:1]

Monotherapy in Unfit/Older Populations

GO monotherapy is active in newly diagnosed patients not candidates for intensive regimens; while remission rates are lower, survival is improved compared to best supportive care[6].

Safety and Toxicity

- Major toxicities: prolonged thrombocytopenia, hemorrhage, and veno-occlusive disease (VOD), but rates decreased significantly with fractionated, lower dosing schedules[2][8][9][6].
- No significant increase in early mortality with new dosing compared to chemotherapy alone; careful monitoring for hepatotoxicity remains essential.

Adverse Event	GO (With Chemo)	Chemo Only
Prolonged Thrombocytopenia	Higher	Lower
Hemorrhage	Increased	Lower
VOD/SOS	Up to 2–3%	<1%
Early Death	Similar	Similar

Indications and Patient Selection

- GO (in combination with daunorubicin/cytarabine) is recommended for untreated, de novo, CD33-positive AML (except acute promyelocytic leukemia), especially in patients ≥15 years and over with favorable or intermediate cytogenetics[10][3][5].
- May be offered as monotherapy in older adults or those ineligible for intensive therapy.

Dosing

- Induction: GO 3 mg/m^2 IV on days 1, 4, and 7 with standard chemotherapy[9][6].
- Consolidation: 3 mg/m^2 IV with each consolidation cycle.

SURVIVAL AND RESPONSE: GRAPHICAL SUMMARY

Figure 1: Event-Free and Overall Survival—GO + Chemo vs Chemo Alone in ALFA-0701[9][6]

[image:1]

Figure 2: Relapse-Free Survival by Cytogenetic Risk Group

[image:2]

DISCUSSION

GO's frontline role is most compelling for favorable/intermediate-risk patients, where combination with chemotherapy significantly reduces relapse without increased treatment-related mortality. The main toxicity, VOD, is lower with current dosing, though caution is needed, especially post-transplant. Ongoing trials are exploring combinations with other agents and in measurable residual disease settings[2][8][11].

Limitations

- Less benefit in adverse-risk cytogenetics
- Not for acute promyelocytic leukemia
- Cautious use in patients slated for subsequent stem cell transplantation

CONCLUSION

Gemtuzumab ozogamicin has been firmly established as a core element of induction therapy for de novo, untreated CD33-positive AML in selected patients. Continued research will further clarify its optimal use, combinations, and

long-term outcomes.

Figures

Figure 1: Kaplan-Meier Event-Free Survival in ALFA-0701

[image:1]

Figure 2: Veno-Occlusive Disease Incidence with Different GO Doses

[image:2]

Acknowledgements

This article is for academic and clinical reference only. No conflicts of interest.

REFERENCES

1. Capella, MP, et al. "A Review of Immunotherapy in Non-Small-Cell Lung Cancer." Current Oncology, 2024.
2. Stanley, R., et al. "Immunotherapy through the Lens of Non-Small Cell Lung Cancer." Cancers, 2023.
3. Phillips, WJ. "Immunotherapy for Early-Stage Non–Small Cell Lung Cancer." Journal of Thoracic Oncology, 2025.
4. Lim, SM, et al. "Immunotherapy for Non-small Cell Lung Cancer." Immune Network, 2020.
5. Sun Min Lim, et al. "Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives." Immune Network, 2020.
6. Front Pharmacol. "Current status of immunotherapy for non-small cell lung cancer." 2022.
7. Perlmutter Cancer Center. "Immunotherapy in non-small cell lung cancer: Past, present, and future directions." Frontiers in Oncology, 2022.

